GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

Stock Information for GT Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GT Biopharma Inc.

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit
GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GT Biopharma Reports Second Quarter 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.